SAS Output

20-AUG-2018 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 90 0 0 0 0 BREAST
        9383 90 0 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 36 0 0 0 0  
      3 Endocrine Therapy Alone 2536 38 0 0 0 0  
        5083 74 0 0 0 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 833 175 86 37 12 3 BREAST
      2 Blinded drug + Endocrine 842 188 82 38 9 3  
        1675 363 168 75 21 6  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 5 4 1 0 0 0 SURV
      2 Randomization Non-surgical M 6 5 1 1 1 1  
      3 Patient Choice Surgery 47 15 10 2 1 0  
      4 Patient Choice Non-surgical M 100 31 6 0 0 0  
        158 55 18 3 2 1  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 539 253 138 59 12 4 CCD
      2 Site randomized: Control 367 217 94 51 11 1  
      3 SiteRand Int Risk: CSF 644 460 216 86 25 4  
      4 SiteRand Int Risk: No CSF 493 359 184 79 25 8  
        2043 1289 632 275 73 17  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 292 201 113 45 11 2 CCD
        292 201 113 45 11 2  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 293 233 135 68 28 4 BREAST
        293 233 135 68 28 4  
 
  2 Y 2 Observation 124 100 58 28 8 1  
      3 MK-3475 (Pembrolizumab) 121 94 56 30 9 3  
        245 194 114 58 17 4  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 26 26 21 16 2 1 SURV
        26 26 21 16 2 1  
 
  2 Y 1 Carvedilol 6 6 4 4 2 0  
      2 No intervention 5 5 3 2 1 0  
      3 Observation 13 13 12 10 1 0  
        24 24 19 16 4 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 45 37 21 9 5 0 GU
      2 Tokyo-172 BCG 45 38 23 12 4 0  
      3 Prime + Tokyo-172 BCG 45 38 22 11 4 1  
        135 113 66 32 13 1  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y   0 0 0 0 0 0 CCD
        0 0 0 0 0 0  
 
  2 Y   0 0 0 0 0 0  
        0 0 0 0 0 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 498 103 27 9 2 0 PREV
        498 103 27 9 2 0  
 
  1 Y 1 Blinded drug 67 24 11 7 0 0  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 70 27 11 7 1 0  
        208 51 22 14 1 0  
 

20-AUG-2018 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1703-Met Breast, STM-monitoring v Usual Care regtype: 1
S1703-Met Breast, STM-monitoring v Usual Care regtype: 2